DexCom reiterates $5.16B-$5.25B 2026 revenue outlook while raising operating margin to 23%-23.5%

Q1 2026 Management view DexCom reported Q1 momentum tied to coverage expansion, product rollout, and operational execution, with President, CEO & Director Jacob Leach highlighting “first quarter ...
San Diego Union-Tribune

Dexcom starts selling its new over-the-counter glucose monitor. Here’s how much it costs

San Diego’s Dexcom began sales this week of Stelo, the industry’s first FDA-approved continuous glucose monitor that doesn’t require a prescription. With a two-pack of the biosensor costing just under ...
Drug Delivery Business

Dexcom stock dips after hours despite Q1 beats, 15% sales growth

Dexcom (Nasdaq:DXCM) today posted first-quarter financial results that came in ahead of the Wall Street forecast.
The Motley Fool

Where Will DexCom Be in 5 Years?

DexCom will likely make significant headway in its addressable market in the next five years. The company should also increase its reach by launching new products and entering new countries. Despite a ...
Business Wire

Dexcom Schedules Third Quarter 2024 Earnings Release and Conference Call for October 24, 2024 at 4:30 p.m. Eastern Time.

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its third quarter 2024 financial results after market close on Thursday, October 24, 2024. Management ...
Business Wire

Dexcom Smart Basal Receives FDA Clearance Becoming the First and Only CGM-integrated Basal Insulin Dosing Optimizer for Type 2 Diabetes

Dexcom Smart Basal is designed to make basal insulin initiation and management simpler and more personalized for users and their healthcare providers. * Dexcom Smart Basal is FDA cleared and now the ...